Last reviewed 2026-04-20 · How we verify

Mucolitico (DOMIODOL)

Phase 2 active Small molecule Quality 24/100

Mucolitico (generic name: DOMIODOL) is a domiodol drug. It is currently in Phase 2 development.

Mucolitico works by breaking down and dissolving mucus in the body.

Mucolitico (DOMIODOL) is a small molecule drug in the domiodol class, developed by an unknown entity and currently owned by an unknown entity. Its target and exact mechanism of action are not specified. Mucolitico is used to treat unknown indications, and its commercial status, including patent status and generic availability, is unclear. Key safety considerations are also unknown. Further research is needed to fully understand this medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DOMIODOL
Drug class	domiodol
Modality	Small molecule
Therapeutic area	Respiratory
Phase	Phase 2

Mechanism of action

Imagine your body's mucus as a sticky, thick glue that can clog up your airways or digestive system. Mucolitico helps to break down this glue, making it easier to expel and relieving congestion and discomfort. This can be especially helpful for people with conditions like chronic bronchitis or cystic fibrosis.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Mucolitico CI brief — competitive landscape report
Mucolitico updates RSS · CI watch RSS

Frequently asked questions about Mucolitico

What is Mucolitico?

Mucolitico (DOMIODOL) is a domiodol drug.

How does Mucolitico work?

Mucolitico works by breaking down and dissolving mucus in the body.

What is the generic name of Mucolitico?

DOMIODOL is the generic (nonproprietary) name of Mucolitico.

What drug class is Mucolitico in?

Mucolitico belongs to the domiodol class. See all domiodol drugs at /class/domiodol.

What development phase is Mucolitico in?

Mucolitico is in Phase 2.

Drug class: All domiodol drugs
Therapeutic area: All drugs in Respiratory

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing